Products for Research Use Only
RegisterLogin

Fenebrutinib

CAT: 0804-HY-19834-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19834-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research[1].
CAS Number
1434048-34-6
Product Name Alternative
GDC-0853
UNSPSC
12352005
Hazard Statement
H315, H317, H318, H334, H335, H341, H361, H370, H413
Target
Btk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/GDC-0853.html
Purity
99.89
Solubility
DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C1C(NC(C=C2)=NC=C2N3CCN(C4COC4)C[C@@H]3C)=CC(C5=CC=NC(N6C(C7=CC(CC(C)(C)C8)=C8N7CC6)=O)=C5CO)=CN1C
Molecular Formula
C37H44N8O4
Molecular Weight
664.80
Precautions
H315, H317, H318, H334, H335, H341, H361, H370, H413
References & Citations
[1]Erickson RI , et al. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats. J Pharmacol Exp Ther. 2017 Jan;360 (1) :226-238.|[2]Crawford JJ, et al. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development. J Med Chem. 2018 Mar 22;61 (6) :2227-2245.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
F247550Fenebrutinib
TQ0242LFenebrutinib HCl
C13408-100mgFenebrutinib (GDC-0853)
206475Fenebrutinib free base

Popular Products